  |
||||||||
|
Orchid Chemicals & Pharmaceuticals Ltd. |
||||||||
|
Audited Financial Results for the year ended March 31, 2006
|
||||||||
| S.No |
Particulars
|
Nine months ended
31-Dec-05 (unaudited) |
Three Months ended
31-Mar-06 (unaudited) |
Three
Months ended
31-Mar-05 (unaudited)
|
Year ended
31-Mar-06 (Audited)
|
Year ended
31-Mar-05 (Audited)
|
Consolidated year ended
31-Mar-06 (Audited)
|
Consolidated year ended
31-Mar-05 (Audited)
|
|
1
|
Sales and Operating Income |
64885.21
|
23984.87
|
17810.49
|
88870.08
|
68929.44 |
95187.43
|
73396.57
|
|
2
|
Other Income |
37.62
|
100.49
|
18.84
|
138.11
|
82.24
|
127.29
|
86.81
|
|
3
|
Total Expenditure |
45873.60
|
17074.52
|
13676.42
|
62948.12
|
52700.71
|
71512.57
|
57751.62
|
|
a) Decrease/(Increase) in Stock in trade |
(4008.31)
|
2095.59
|
(5475.15)
|
(1912.72)
|
(9837.95)
|
(2048.83)
|
(10467.95)
|
|
| b) Consumption of raw materials |
29705.16
|
6734.06
|
12430.37
|
36439.22
|
39400.50
|
42983.66
|
43780.08
|
|
| c) Staff Cost |
4755.06
|
1775.85
|
1341.24
|
6530.91
|
5438.09
|
6973.62
|
5548.59
|
|
| d) Other Expenditure |
15421.69
|
6469.02
|
5379.96
|
21890.71
|
17700.07
|
23604.12
|
18890.90
|
|
|
4
|
Profit before Interest, Depreciation & Tax
(1+2-3)
|
19049.23
|
7010.84
|
4152.91
|
26060.07
|
16310.97
|
23802.15
|
15731.76
|
|
5
|
Interest and Finance Charges |
6697.49
|
2003.83
|
1858.43
|
8701.32
|
7231.00
|
8784.48
|
7354.58
|
|
6
|
Depreciation/Amortisation |
5690.18
|
2607.39
|
1553.70
|
8297.57
|
6189.20
|
8516.66
|
6378.30
|
|
7
|
Profit before tax |
6661.56
|
2399.62
|
740.78
|
9061.18
|
2890.77
|
6501.01
|
1998.88
|
|
8
|
Provision for Taxation |
|
|
|
|
|||
| - Current Tax |
56.83
|
194.60
|
194.60
|
|||||
| - Deferred Tax |
180.00
|
410.00
|
(975.74)
|
590.00
|
(404.93)
|
590.00
|
(404.93)
|
|
| - Fringe Benefit Tax | 130.00 |
51.00 |
181.00 |
181.00 |
||||
|
9
|
Net Profit (7-8) |
6351.56
|
1938.62
|
1659.69
|
8290.18
|
3101.10
|
5730.01
|
2209.21
|
|
10
|
Paid- up Equity Share Capital (Face value of Rs. 10 each) |
6150.55
|
6461.82
|
3413.19
|
6461.82
|
3413.19
|
6461.82
|
3413.19
|
|
11
|
Reserves excluding Revaluation Reserves |
|
|
|
72499.40
|
43714.20
|
71555.58
|
42883.64
|
|
12
|
Basic Earnings per Share (EPS) Rs. |
10.33*
|
3.47*
|
3.40**
|
14.85
|
6.36**
|
10.27
|
4.53**
|
|
13
|
Diluted Earnings per share (EPS) Rs.
|
9.46*
|
3.19*
|
3.23**
|
13.64
|
6.15**
|
9.43
|
4.30**
|
| 14 |
Aggregate of Non-Promoter Shareholding |
53124009 |
27495965 |
|||||
|
82.21
|
80.56
|
|||||||
| *EPS is for the period (not annualised)
after providing for taxes ** EPS for earlier periods adjusted for the bonus issue |
||||||||
| 1 | The above financial results were adopted by the Board of Directors at its meeting held on Friday, April 28, 2006. | |||||||||
| 2 | The Board of Directors have recommended a dividend of 30% (Rs 3/-per share) on the equity share of Rs 10/- each. | |||||||||
| 3 | The Allotment Committee of
the Board have allotted shares as follows: - 1,84,330 and 4,60,827 equity shares on March 01, 2006 and March 07, 2006 on conversion of US$ 1,000,000 and US$ 2,500,000 Zero Coupon FCCBs respectively - 17,51,146 and 6,52,531 equity shares on March 20, 2006 and March 31, 2006 on conversion of US$ 9,500,000 and US$ 3,540,000 Zero Coupon FCCBs respectively -4,14,744 and 7,37,325 equity shares on April 18, 2006 and April 28, 2006 on conversion of US$ 2,250,000 and US$ 4,000,000 Zero Coupon FCCBs respectively -50,000 equity shares at an adjusted price of Rs. 226.28/- to Promoter / Promoter group(s) on March 20, 2006 on conversion of warrants -13,879 shares (6720 shares at an adjusted price of Rs.162.24/- per share and 7159 shares at an adjusted price at Rs.168/- per share) to employees under ORCHID ESOP 1999 Scheme, on March 31, 2006 -3,475 shares (2250 shares at an adjusted price of Rs.162.24/- per share and 1225 shares at an adjusted price at Rs.168/- per share) to employees under ORCHID ESOP 1999 Scheme on April 28, 2006 |
|||||||||
| 4 | The Compensation Committee of the Board at its meeting held on April 28, 2006 approved the issue of 3,00,000 stock options to employees. The stock options are convertible into equity shares of Rs. 10/- each at a price of Rs. 339.25 per share | |||||||||
| 5 | The Company 's increasing level of exports to regulated markets is in the form of finished dosage forms (formulations) which utilised the Company's active pharmaceutical ingredients (bulk drugs). In view of the integration of bulk actives and formulation business segments, the Company considers the business as one integrated business of "Pharmaceutical Products" and hence no separate segmental reporting is provided | |||||||||
| 6 | The Company received 36 complaints during the quarter ended March 31, 2006 from the shareholders. All the complaints have been resolved and no complaints were pending as on March 31, 2006 | |||||||||
| 7 | Previous period figures have been regrouped wherever necessary. | |||||||||
|
||||||||||